ProShare Advisors
CERE

ProShare Advisors’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

ProShare Advisors’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-15,422
Closed -$631K – 2140
2024
Q2 		$631K Sell
15,422
-3,716
-19% -$155K ﹤0.01% 867
2024
Q1 		$809K Buy
19,138
+41
+0.2% +$1.72K ﹤0.01% 855
2023
Q4 		$810K Buy
+19,097
New +$549K ﹤0.01% 814
2023
Q3 		– Sell
-8,048
Closed -$256K – 1875
2023
Q2 		$256K Buy
+8,048
New +$247K ﹤0.01% 1379
2023
Q1 		– Sell
-7,372
Closed -$233K – 1930
2022
Q4 		$233K Buy
+7,372
New +$208K ﹤0.01% 1388
2022
Q2 		– Sell
-7,642
Closed -$268K – 2194
2022
Q1 		$268K Sell
7,642
-1,259
-14% -$36.8K ﹤0.01% 1701
2021
Q4 		$289K Buy
+8,901
New +$314K ﹤0.01% 1815
2021
Q3 		– Sell
-9,148
Closed -$234K – 2316
2021
Q2 		$234K Buy
+9,148
New +$131K ﹤0.01% 2050

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

ProShare Advisors's CERE Position: Q3 2024 in Review

ProShare Advisors sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 15,422 shares — an estimated $631K sold.

ProShare Advisors first reported a position in CERE in Q2 2021 and held it in 8 quarters. The position peaked at $810K in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • ProShare Advisors reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • ProShare Advisors sold 15,422 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $631K.
  • ProShare Advisors first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
  • ProShare Advisors's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $810K in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on ProShare Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.